Gapping up
In reaction to strong earnings/guidance: CHRS +24.2%, VCEL +16.1%, DGLY +15.3%, (also files for $25 mln mixed securities shelf offering) EPRS +5.8%, IHS +5.8%, MKC +2.7%, EGL +2.6%, GNVC +1.2%, FLXN +1%, GIII +0.8%
Select EU bell weather names showing strength: ING +1.8%, DB +1.6%, NOK +1.4%, SAP +1.2%, SAN +1.1%, ASML +1%, DEO +0.9%, UN +0.9%
Select oil/gas stocks trading higher: PBR +1.7%, SDRL +1.6%, WTI +1.4%, STO +1.1%, COP +0.8%, CVX +0.7%
Other news: ISR +14.8% (announces it will host a dinner presentation describing the use, procedure and outstanding results in treating gynecologic cancers utilizing Cesium-131), NEPT +12.6% (USPTO issues positive decision that triggers royalty payments to Neptune), GSBD +7.9% (announces closing of IPO, confirms quarterly distribution of $0.45/share), VOXX +7.8% (co's iris authentical product, EyeLock, was mentioned positively on CNBC), ATOS +7.1% (launches the FullCYTE Breast Aspirator in the United States), ABMD +6.2% (confirmed Impella 2.5 received FDA approval for elective and urgent high risk percutaneous coronary intervention procedures), LOGI +5% (product announcement), RADA +4.8% (announces the selection by Lockheed Martin (LMT) Space Systems Company of its Multi-Mission Hemispheric Rada to support internally funded high energy laser weapon system prototype testing), CHK +4.1% (reduced 2015 CapEx budget to $3.5-4.0 bln from $4.0-4.5 bln; Carl Icahn increased stake to 10.98% from 9.98%), LINE +3.9% (announces $1 billion equity commitment from Quantum Energy Partners to form strategic acquisition alliance), ATNM +3.7% (announces that it is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia in patients over the age of 60), ARIA +3.6% (co and Medison Pharma announce that the Israeli Ministry of Health has granted regulatory approval for Iclusig (ponatinib) in Israel), PSTI +3.5% (announces key strategic objectives for development of PLX-R18 in hematopoietic indications), MCP +3.3% (cont strength), EGL +2.6% (co was awarded an Indefinite Delivery Indefinite Quantity multiple-award contract with a $1 bln ceiling to provide technical advisory services to the U.S. Agency for International Development), NVO +2.2% (Saxenda approved yesterday in Europe for the treatment of obesity), GILT +1.8% (Chairman, Dov Baharav, will assume the position of interim CEO, as Erez Antebi decides to step down )
Analyst comments: HIG +1% (resumed with a Buy at Goldman), XEL +0.9% (upgraded to Overweight from Equal Weight at Barclays), EL +0.8% (upgraded to Outperform from Market Perform at Wells Fargo)
In reaction to strong earnings/guidance: CHRS +24.2%, VCEL +16.1%, DGLY +15.3%, (also files for $25 mln mixed securities shelf offering) EPRS +5.8%, IHS +5.8%, MKC +2.7%, EGL +2.6%, GNVC +1.2%, FLXN +1%, GIII +0.8%
Select EU bell weather names showing strength: ING +1.8%, DB +1.6%, NOK +1.4%, SAP +1.2%, SAN +1.1%, ASML +1%, DEO +0.9%, UN +0.9%
Select oil/gas stocks trading higher: PBR +1.7%, SDRL +1.6%, WTI +1.4%, STO +1.1%, COP +0.8%, CVX +0.7%
Other news: ISR +14.8% (announces it will host a dinner presentation describing the use, procedure and outstanding results in treating gynecologic cancers utilizing Cesium-131), NEPT +12.6% (USPTO issues positive decision that triggers royalty payments to Neptune), GSBD +7.9% (announces closing of IPO, confirms quarterly distribution of $0.45/share), VOXX +7.8% (co's iris authentical product, EyeLock, was mentioned positively on CNBC), ATOS +7.1% (launches the FullCYTE Breast Aspirator in the United States), ABMD +6.2% (confirmed Impella 2.5 received FDA approval for elective and urgent high risk percutaneous coronary intervention procedures), LOGI +5% (product announcement), RADA +4.8% (announces the selection by Lockheed Martin (LMT) Space Systems Company of its Multi-Mission Hemispheric Rada to support internally funded high energy laser weapon system prototype testing), CHK +4.1% (reduced 2015 CapEx budget to $3.5-4.0 bln from $4.0-4.5 bln; Carl Icahn increased stake to 10.98% from 9.98%), LINE +3.9% (announces $1 billion equity commitment from Quantum Energy Partners to form strategic acquisition alliance), ATNM +3.7% (announces that it is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia in patients over the age of 60), ARIA +3.6% (co and Medison Pharma announce that the Israeli Ministry of Health has granted regulatory approval for Iclusig (ponatinib) in Israel), PSTI +3.5% (announces key strategic objectives for development of PLX-R18 in hematopoietic indications), MCP +3.3% (cont strength), EGL +2.6% (co was awarded an Indefinite Delivery Indefinite Quantity multiple-award contract with a $1 bln ceiling to provide technical advisory services to the U.S. Agency for International Development), NVO +2.2% (Saxenda approved yesterday in Europe for the treatment of obesity), GILT +1.8% (Chairman, Dov Baharav, will assume the position of interim CEO, as Erez Antebi decides to step down )
Analyst comments: HIG +1% (resumed with a Buy at Goldman), XEL +0.9% (upgraded to Overweight from Equal Weight at Barclays), EL +0.8% (upgraded to Outperform from Market Perform at Wells Fargo)